MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$185,000K
(-22.45%↓ Y/Y)
Crysvita
$46,000K
(-16.49%↓ Y/Y)
Evkeeza
$18,000K
(63.18%↑ Y/Y)
Dojolvi
$18,000K
(5.83%↑ Y/Y)
Mepsevii
$7,000K
(-16.54%↓ Y/Y)
Loss before income
taxes
-$184,000K
(-22.86%↓ Y/Y)
Provision for income taxes
$1,000K
(-23.66%↓ Y/Y)
Interest income
$6,000K
(-12.17%↓ Y/Y)
Product
$89,000K
(-2.74%↓ Y/Y)
Crysvita-Royalty
$47,000K
(-1.64%↓ Y/Y)
Loss from operations
-$169,000K
(-18.23%↓ Y/Y)
Non-cash interest
expense on liabilities...
$21,000K
(46.42%↑ Y/Y)
Total revenues
$136,000K
(-2.36%↓ Y/Y)
Total operating
expenses
$305,000K
(8.07%↑ Y/Y)
Research and development
$187,000K
(12.81%↑ Y/Y)
Selling, general and
administrative
$88,000K
(0.23%↑ Y/Y)
Cost of sales
$30,000K
(4.67%↑ Y/Y)
Back
Back
Income Statement
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
source: myfinsight.com